Elizabeth Fritz
Nurse Practitioner · Bloomsburg, PANPI 1194962779
Payments from drug & device makers
Across 421 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Amgen$586
- AstraZeneca$563
- Lilly USA, LLC$489
- Boehringer Ingelheim$450
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,535100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,429 |
| Novo Nordisk | 69 | $1,112 |
| Amgen | 39 | $586 |
| AstraZeneca(2 entities) | 25 | $563 |
| Lilly USA, LLC | 27 | $489 |
| Boehringer Ingelheim | 27 | $450 |
| Abbott | 21 | $403 |
| Bayer | 17 | $361 |
| Pfizer | 20 | $299 |
| GSK | 11 | $196 |
| Exact Sciences | 8 | $181 |
| Phathom Pharmaceuticals, Inc. | 8 | $155 |
| Merck | 9 | $151 |
| Dexcom, Inc. | 5 | $121 |
| Johnson & Johnson(2 entities) | 7 | $105 |
| Esperion Therapeutics, Inc. | 5 | $94 |
| Sanofi-aventis U.S. LLC | 6 | $89 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Astellas Pharma US Inc | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $54 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Boston Scientific | 1 | $53 |
| Indivior Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $33 |
| Novartis | 2 | $28 |
| Biogen | 2 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $24 |
| Curonix LLC | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $17 |
| Optinose US, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,535 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $97,339 |
| JardianceEmpagliflozin | 64 | $63,324 |
| RybelsusSemaglutide | 39 | $59,839 |
| EliquisApixaban | 76 | $56,029 |
| MounjaroTirzepatide | 21 | $31,786 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $31,245 |
| FarxigaDapagliflozin Propanediol | 26 | $29,307 |
| KerendiaFinerenone | 19 | $17,270 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,002 |
| JanuviaSitagliptin Phosphate | 16 | $11,005 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $7,332 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,256 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,389 |
| Varenicline Tartrate | 14 | $4,667 |
| Atorvastatin Calcium | 252 | $3,910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,112 | $157,17798 claims |
| Boehringer IngelheimJardiance | $450 | $63,32464 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $563 | $60,55357 claims |
| PfizerEliquis | $299 | $56,02976 claims |
| Lilly USA, LLCMounjaro | $489 | $31,78621 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $196 | $20,25834 claims |
| BayerKerendia | $361 | $17,27019 claims |
| MerckJanuvia | $151 | $11,00516 claims |
| AbbVieSynthroid | $1,429 | $1,37818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Bloomsburg
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.